



1 Article

# 2 **Vimentin plays a crucial role in fibroblast ageing by** 3 **regulating biophysical properties and cell migration**

4 **Kristina Sliogeryte and Núria Gavara \***

5 School of Engineering and Materials Science, Queen Mary University of London, Mile End Road, E1 4NS,  
6 London, UK

7 \* Correspondence: [n.gavara@qmul.ac.uk](mailto:n.gavara@qmul.ac.uk); Tel.: +44(0) 207 882 6596

8 Received: date; Accepted: date; Published: date

9 **Abstract:** Ageing is the result of changes in biochemical and biophysical processes at the cellular  
10 level that lead to progressive organ decline. Here we focus on the biophysical changes that impair  
11 cellular function of human dermal fibroblasts using donors of increasing age. We find that cell  
12 motility is impaired in cells from older donors, which is associated with increased Young's  
13 modulus, viscosity and adhesion. Cellular morphology also displays parallel increases in spread  
14 area and cytoskeletal assembly, with a 3-fold increase in vimentin filaments alongside a decrease in  
15 its remodelling rate. Treatments with withaferin A or acrylamide show that cell motility can be  
16 modulated by regulating vimentin assembly. Crucially, decreasing vimentin amount in cells from  
17 older individuals to levels displayed by the neonatal donor rescues their motility. Our results  
18 suggest that increased vimentin assembly may underlay the aberrant biophysical properties  
19 progressively observed at the cellular level in the course of human ageing and propose vimentin as  
20 a potential therapeutic target for ageing-related diseases.

21 **Keywords:** fibroblasts; cell ageing; vimentin; actin; tubulin; cell migration; cell mechanics;  
22 withaferin A; acrylamide

---

## 24 1. Introduction

25 Ageing is a complex process characterised by temporal changes in biological, biophysical and  
26 biochemical function that lead to a progressive whole-body decline throughout the lifespan of an  
27 individual. While age-related deterioration is most conspicuous at the organ level, it has been  
28 hypothesized that the underlying causes are likely to be dysfunctions at the cellular and tissue level  
29 [1]. Age is a risk factor for many pathologies such as cardiovascular disease [2], osteoarthritis [3],  
30 idiopathic pulmonary fibrosis [4], glaucoma [5] and cancer [6]. Possibly due to the links between  
31 pathology and ageing, the majority of ageing research has focused on assessing decline in organ or  
32 tissue function and associating it to changes in genetic, epigenetic or metabolic states. On the other  
33 hand, cellular behaviour integrates as a simpler output the plethora of molecular networks and gene  
34 up/down regulations that define the molecular state of a cell. Accordingly, complex age-associated  
35 perturbations at the molecular level may be more easily captured as aberrations at the cellular level.  
36 In spite of that, a limited number of studies have assessed age-associated changes in cell behaviour.

37 The majority of cellular studies on ageing have focused on recursive passaging *in vitro* as a  
38 surrogate of ageing *in vivo* [7–10]. Conversely, comprehensive studies of single cells isolated from  
39 donors at different ages have been limited, and tend to focus on measuring replicative decline or the  
40 emergence of senescence within a cell population [11]. Recent studies have demonstrated that donor  
41 age can be determined using biophysical biomarkers such as cell migration, contractility,  
42 mechanical properties and gross morphological features [12,13] It thus follows from those findings  
43 that biophysical properties do change significantly and become aberrant as a result of donor ageing  
44 [14,15], a phenomenon that likely impairs cell function.

45 It is often assumed that actin is the main cytoskeletal network involved in the regulation of cell  
46 motility [16,17], the generation of contractile forces and in overall cell biophysical properties  
47 [18,19]. Recent studies have revealed that microtubules and especially the intermediate filament  
48 vimentin also play a crucial role in functions ranging from cell motility to signal transduction. Of  
49 late, vimentin has been reported to be involved in cell migration by regulating acto-myosin  
50 contraction forces, interactions with the extracellular matrix, and also in the ability of the cell to  
51 move its nucleus forward [20,21]. Other studies have highlighted vimentin's role in wound healing  
52 by coordinating fibroblast proliferation [22] or in collective cell migration by controlling traction  
53 forces [23]. Interestingly, it has been suggested that vimentin fibres are the major contributor to  
54 cytoplasmic but not cortical stiffness of cells, given that the cytoplasm of wild-type fibroblasts is  
55 2-fold stiffer than that of their vimentin-deficient counterparts, even though cortical stiffness  
56 remains the same [24]. Vimentin-deficient cells also show defects in cell motility and directionality as  
57 well as a reduction in wound healing capacity [25,26] while overexpression of vimentin promotes  
58 prostate cancer cell invasion and metastasis [27]. Finally, vimentin has also been linked to ageing,  
59 with observations that senescent cells show increased levels of vimentin expression [28] and that  
60 glycation of vimentin is increased in fibroblast from old donors [29].

61 In this study, we used a combination of biophysical approaches to assess how cell morphology  
62 and biophysical behaviour are altered due to ageing. Human dermal fibroblast from donors of  
63 different ages were used as a model to characterize how changes in cell motility and biophysical  
64 properties are associated to changes in cytoskeleton organisation. Fibroblast from older donors had  
65 reduced cell motility and increased cell stiffness, which was associated to changes in cytoskeletal  
66 assembly. In particular the age-associated aberrations in cell motility and biophysical properties  
67 appeared alongside vimentin accumulation, and could be rescued using drugs believed to primarily  
68 target vimentin. Our findings suggest the importance of vimentin in donor ageing and point  
69 towards this cytoskeletal protein and associated signaling pathways as a potential biomarkers for  
70 the diagnosis, prognosis and treatment of a wide variety of different diseases associated with ageing.

## 71 2. Materials and Methods

### 72 2.1. Cell lines and culture

73 Human dermal fibroblasts were obtained from commercial sources. In brief, cells were derived  
74 from temple or labia tissue from 'apparently healthy' caucasian female donors. Neonatal (N) and  
75 adult age 62 (A62) cells were purchased from Lonza Biologics, while adult age 21 (A21) and age 47  
76 (A47) cells were purchased from PromoCell. Vials of cells were shipped at passage 2 and all  
77 experiments were carried out in cells up to passage 7. NIH 3T3 cells were a gift from A.Mata group  
78 (Queen Mary University of London). All cell work was conducted in identical conditions among all  
79 donors and culturing of cells was carried out in parallel. Cells were cultured on plastic plates in high  
80 glucose (4.5g/L) DMEM medium (Gibco) supplemented with 10% foetal bovine serum (FBS) (Sigma)  
81 and 1% penicillin/streptomycin.

### 82 2.2. Cell transfection

83 Cells were transfected with actin (pCAG-mGFP-Actin, 21948, AddGene) or vimentin  
84 (pVimetin-PSmOrange, 31922, AddGene) plasmids. Cells were seeded at low density (2,000-5,000  
85 cells/cm<sup>2</sup>) onto 6-well tissue culture treated plates in antibiotic free medium and allowed to adhere  
86 overnight. After cells were transfected with plasmids using a specific dermal fibroblast transfection  
87 reagent (EZBiosystems). The concentrations of plasmids and reagent was scaled down according to  
88 the number of cells per well. The transfection was allowed for 6 hours and after the fresh antibiotic  
89 free medium was replaced. All live experiments with transfected cells were performed 48 hours after  
90 transfection.

91

### 92 2.3. Cell migration

93 Transfected cells were seeded onto 6-well plate at low density. Prior to imaging, the medium  
94 was replaced with FBS supplemented Flurobrite-DMEM imaging specific medium (Thermofisher) to  
95 reduce background fluorescence and photobleaching. Time-lapse recordings of single cell dynamics  
96 were acquired with a 20x objective by a Lumascope LS720 microscope (Etaluma) at a rate of 1 image  
97 every 10 minute for at least 6 hours. The miniaturized microscope is placed inside the incubator, so  
98 temperature and CO<sub>2</sub> concentration are maintained throughout the time-lapse experiment.

99 For wound healing assays, cells were seeded at 25000 cells/cm<sup>2</sup> on 12-well plates with attached  
100 PDMS stencils and incubated for 2 days to confluence. The “wound” was initiated by removing the  
101 PDMS stencil and the medium was aspirated and changed with fresh one. Cell migration was  
102 monitored by taking images every 30 minutes for 100 hours.

103 The algorithm to analyze time-lapse fluorescence videos is based on grey-scale images of the  
104 fluorescent channels and there are two steps: (1) determination of the cell outlines for every frame,  
105 (2) calculation of the positions of cell centroids. Once the position of the cell’s centroid was  
106 determined for each frame, we computed the cell’s instantaneous migration speed and the  
107 persistence of the overall recorded migration path as previously described elsewhere [30]. In brief,  
108 migration persistence is defined as the ratio between net cell displacement (the euclidian distance  
109 between starting and ending centroid positions) and the overall distance travelled by the cell, as  $P =$   
110  $\frac{d(X_{t=0}, X_{t=T})}{\sum_{i=0}^{T-1} d(X_{t=i}, X_{t=i+1})}$ . Persistence values are thus unitless and bound between 0 (random migration) and 1  
111 (straight line). For scratch assay experiments, the wound healing area (area not covered by cells) was  
112 calculated at 0, 24, 48, 75 and 99 hours using and ImageJ script.

#### 114 2.4. Cell viscoelastic properties with atomic force microscopy

115 Atomic force microscopy (AFM) was employed to investigate the biophysical properties of  
116 human dermal fibroblasts. The AFM system (NanoWizard4, JPK, Germany) was mounted on a Zeiss  
117 epifluorescence microscope. Images of live, healthy fibroblasts were scanned under liquid  
118 conditions (DMEM medium with 25 mM Hepes supplemented with 10% FBS and 1%  
119 penicillin/streptomycin) at 37°C with the V shaped gold coated silicon nitride cantilevers (Budget  
120 Sensors) with four-sided pyramidal tips in contact mode. The cantilever had a spring constant of 0.06  
121 N/m, length of 200 μm and width of 30 μm. The spring constant of the cantilever was calibrated  
122 using the thermal fluctuations method based on sensitivity calculation on the bare region of the  
123 substrate. Force maps of the cells were taken in quantitative imaging (QI) mode at a resolution of 32  
124 × 32 pixels, using 4000 nm ramp length, 250 μ/s ramp speed and a force setpoint of 2 nN. Using these  
125 conditions, maximum indentation levels reached were ~2 μm, typically on the vicinity of the nucleus  
126 of the softest cells probed. The scan area depended on the cell size, with the maximum attainable  
127 range being 100 × 100 μm<sup>2</sup>. If the cell exceeded that range, half or a quarter of cell was chosen  
128 including always a portion of the cell nucleus as well as the cell edge (Figure S1).

129 Biophysical properties such as Young’s modulus (E), viscosity (η) and non-specific adhesion  
130 work were determined from the force-distance curves. The force distance curves were analysed  
131 using the BECC model for thin adherent cells on a stiff substrate [31], using a pipeline written in  
132 MATLAB as previously described [32]. Determination of Young’s modulus for the cell cytoskeleton  
133 (E<sub>csk</sub>) and the cell cortex (E<sub>cort</sub>) was based on the approach proposed in Pogoda *et al.* [33]. In  
134 particular, and after the contact point has been identified, E<sub>cort</sub> is obtained by fitting the  
135 force-indentation curve for data points corresponding to indentations <400nm, whereas E<sub>csk</sub> is  
136 obtained by fitting the force-indentation curve for data points corresponding to indentations  
137 >750nm. Cellular viscosity was determined from force distance curves using the method described  
138 by Rebelo *et al.* [34].

#### 139 2.5. Immunofluorescence staining and imaging

140 Dermal fibroblast samples were prepared by seeding cells at low density (5000 cells/cm<sup>2</sup>) on 13  
141 mm glass coverslips. The coverslips were coated with type I collagen at 10 μg/ml concentration for 1

142 hours at 37°C. After rinsed with PBS, cells seeded and allowed to adhere for 24 hours. For drug  
143 treatment experiments, cells were seeded at the low density 24 hours prior drug treatment. Cells  
144 were treated with 1  $\mu$ M, 2.5  $\mu$ M and 5  $\mu$ M concentration of withaferin A and with 2 mM, 4 mM and 6  
145 mM concentrations of acrylamide for 3 hours. Then cells were fixed with 4% paraformaldehyde  
146 (Sigma) for 20 min, washed with PBS, permeabilized with 0.25% Triton X-100 (Sigma) for 10 min,  
147 washed with PBS, and blocked with PBS supplemented with 3% bovine serum albumin (Sigma) for 1  
148 hour at room temperature.

149 For the experiments of cell morphology, cytoskeletons, p21, alpha- smooth muscle actin and  
150 nuclear organization, F-actin filaments were stained with TRITC-tagged Phalloidin (1:1000, Sigma  
151 Aldrich) and co-stained with vimentin monoclonal mouse (1:300, Santa Cruz RV202), tubulin  
152 monoclonal rabbit (1:200, Abcam ab4074) or YAP monoclonal mouse (1:200, Santa Cruz sc-101199),  
153 p21 monoclonal rabbit (1:250, Cell Signaling Technology, 2947) or alpha- smooth muscle actin  
154 monoclonal mouse (1:200, Sigma A2547). Subsequently the secondary antibodies were used  
155 anti-mouse Alexa 488 (Thermo Fisher, A21202) and anti-rabbit Alexa 488 (Thermo Fisher, A21206).  
156 After staining, coverslips were mounted on glass slides with Prolong Gold antifade mounting  
157 medium with DAPI (Thermo Fisher) to protect samples from dry out. Fluorescence images of the  
158 fixed cells were obtained using an inverted epifluorescence microscope (Leica DMI4000B) with  
159 x20/0.5 NA objective lens and a CCD camera (Leica DFC300FX). Images were taken only on well  
160 attached and not damaged cells using DAPI, FITC and TRITC channels.

## 161 2.6. Single cell cytoskeleton quantification analysis

162 Our pipeline for single cell quantification of cytoskeleton and nuclear structures has been  
163 described in detail elsewhere [30]. Briefly, the algorithm uses grey-scale fluorescence  
164 immunostaining-based or live-cell images typically obtained on epifluorescence or confocal  
165 microscopes and it follows three independent steps: (1) initial fiber segmentation, (2) fiber  
166 refinement, and (3) determination and subtraction of non-uniform background within the cell  
167 boundaries. The algorithm outputs data at the single cell level, including gross cell morphology  
168 information like cell area, aspect ratio, and stellate factor or cytoskeleton information like fiber  
169 intensity, length and thickness (for detailed descriptions and examples see [30]). To estimate fibre  
170 thickness in arbitrary units (AU), we measured the average pixel intensities for all pixels identified  
171 by the algorithm as belonging to a fibre. We note that in our imaging conditions, the pixel size is  
172 larger than the diffraction limit or the thickness of a single cytoskeletal filament. Accordingly, the  
173 measurement of fluorescence pixel intensity constitutes a good surrogate measure to estimate the  
174 number of individual fluorophores bound to a fibre and thus number of filaments making up a  
175 stress fibre or bundle. To estimate fibre length in microns, we computed the average length of the  
176 identified stress fibres or filaments in a cell in pixels, and converted them to microns using  
177 previously-measured calibration factors matching the imaging conditions used. For nuclear data, the  
178 pipeline uses the DAPI images and provide estimates on the relative volume (compared to  
179 non-adherent conditions), chromatin condensation or Poisson's ratio. In particular, the algorithm  
180 assumes that the gross morphology of the nucleus can be described as an ellipsoid, and uses changes  
181 in fluorescence pixel intensity along the radial direction of the nucleus to estimate the dimensions of  
182 its 3 semi-axes (for detail see [35]). Note only some of all the parameters output by the pipeline are  
183 used in this manuscript, corresponding to their relevance to the present research question.

## 184 2.7. Cell reattachment experiments

185 The reattachment experiments were carried out using the Lumascope LS720 microscope as  
186 above, using only healthy and well-attached transfected cells. To initiate the reattachment event,  
187 cells were treated with trypsin until they displayed a rounded up shape, but before they were  
188 completely detached. Subsequently, fresh imaging medium was added to the wells and the process  
189 of cell reattachment was imaged. Fluorescence images were recorded every 10 minutes for 6 hours  
190 using a 20x objective.

## 191 2.8. Drug treatments against vimentin

192 Healthy vimentin-transfected and well attached cells were chosen and imaged for 1 hour prior  
193 drug treatment. Subsequently, Withaferin A (Sigma Aldrich) with concentrations of 1  $\mu$ M, 2.5  $\mu$ M  
194 and 5  $\mu$ M, or acrylamide (Bio-Rad) with concentrations of 2 mM, 4 mM and 6 mM was added and  
195 cells were imaged for 6 additional hours. Images were captured every 10 minutes. Cell velocity was  
196 calculated as described above on the same cells before and after drug treatment.

## 197 2.9. Statistical analysis

198 Statistical analysis was performed using GraphPad Prism 5 software. The t-test was used for the  
199 normally distributed data sets, otherwise, the non-parametric Mann-Whitney U test was adopted.  
200 Statistical significance was reported at  $p < 0.05$  (\*),  $p < 0.01$  (\*\*) and  $p < 0.001$  (\*\*\*) unless otherwise  
201 stated. All experiments were performed using at least three replicates unless otherwise mentioned in  
202 the figure legend.


## 203 3. Results

### 204 3.1. Donor age reduces cell migration and increases Young's modulus of human dermal fibroblasts

205 The purpose of this study was to evaluate the biophysical properties of human dermal  
206 fibroblast cells obtained from donors of different ages, obtained at ages: neonatal, 21, 47 and 62  
207 years. To measure the cell velocity of single cells, a miniaturized live imaging system placed inside  
208 an incubator was used to perform long term cell migration experiments in 2D at physiological  
209 conditions. Cells were seeded at low density onto 6-well plates and transfected separately with a  
210 fluorescently-tagged vimentin plasmid. Transfected cells were allowed to recover for 48 hours prior  
211 to migration experiments. Images were taken only of single cells that were clearly transfected,  
212 healthy and well attached. Time-lapse fluorescence images were taken every 10 minutes for 6 hours.  
213 The videos of cell migration were then analysed to measure migration velocity and directionality, by  
214 tracking the non-fluorescent circular area corresponding to the cell nucleus. The results show that  
215 human dermal fibroblast cells from the neonatal donor have a significantly higher velocity  
216 compared to all adult donors. The largest difference (2-fold) was observed when comparing them to  
217 cells from the oldest donor (Figure 1A). Interestingly, cell persistence was affected only when  
218 comparing cells from the neonatal to the oldest donor (Figure 1B). Scratch assays yielded similar  
219 trends, with the oldest donor showing delayed migration into the scratch, even though no  
220 differences were observed for the other donors (Figure S2). Of note, the rate at which the wound  
221 closes is affected by the migration speed of cells, but also by the average spread area of the cells.  
222 Given that both are affected by donor age, our results measuring individual cell migration thus  
223 constitute a less incumbered method and provide clearer results. To rule out that the observed  
224 differences in cell migration were not due to other differences between the primary cells used, we  
225 quantified nuclear expression of p21, as a marker of cell proliferation, and cytoplasmic expression of  
226  $\alpha$ -smooth muscle actin ( $\alpha$ -SMA), as a marker of myogenic differentiation. In both cases, we didn't  
227 observe clear trends with donor age or cell spread area, but found a slight but significant increase on  
228 p21 nuclear expression for the A62 donor (Figure S3) and a slight but significant decrease in  $\alpha$ -SMA  
229 for the A47 donor (Figure S4). Altogether our results suggest that donor age has a significant impact  
230 on cell motility which may delays the capacity of dermal fibroblast to engage in wound healing.

231 Cell motility is associated with changes in biophysical properties, which are regulated by the  
232 cytoskeleton. We therefore examined whether donor age has an effect on cell biophysical properties  
233 using Atomic force microscopy to measure viscoelastic properties. Individual cells from all groups  
234 were probed in QI mode and our customized data-analysis pipeline was used to calculate cell's  
235 Young's modulus (E), viscosity and adhesion work. When determining E, we found that cells from  
236 the oldest donor displayed a 2-fold increase compared to cells from the neonatal donor (Figure 1C).  
237 Similarly, the measurement of cell viscosity showed a significant 1.4-fold increase for cells from  
238 adult donors compared to cells from the neonatal donor (Figure 1D). Furthermore, when evaluating

239 cell adhesion work, we found significant differences also between cells from the neonatal donor  
 240 compared to cells from the oldest donor, the increase being 1.5-fold (Figure 1E). While previous  
 241 studies using immunostaining have demonstrated that adhesion proteins increase in senescent cells  
 242 [36], it is worth pointing out that we report here unspecific adhesion values, given they were  
 243 determined as adhesion strength between the cell membrane and untreated silicon nitride  
 244 cantilevers tips.



245


246 **Figure 1.** Biophysical properties are altered by donor age. (A) Corresponding plot showing reduced  
 247 cell velocity of single fibroblasts on two-dimensional substrates in relation to donor age. Cell  
 248 persistence was significantly different only for cells from oldest donor (B). Data plotted from at least  
 249 three independent experiments as geometric mean with quartiles, cell number varies between  
 250 (50-60). Cells from aged donors exhibited increased viscoelastic properties compared to cells from  
 251 neonatal donor as quantified by significant differences in (C) Young's modulus, (D) viscosity and (E)  
 252 adhesion work estimated using AFM measurement. All data plotted from at least three independent  
 253 experiments as geometric mean with quartiles, \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , Mann Whitney U test. Cell  
 254 number varies between 30-90 with ~12 cells per repeat.

255 Together, our results show that donor age significantly affects biophysical properties, and in  
 256 particular induces a reduction in cell motility alongside increased cell elastic modulus, viscosity and  
 257 adhesion force.

### 258 3.2. Cellular and nuclear morphology of human dermal fibroblasts depend on donor age

259 Changes in donor aging have been linked to alterations in cellular morphology [37] and hence  
 260 we examined whether the observed aberrations in migration and mechanical properties of human  
 261 dermal fibroblasts from older donors were associated with changes on their underlying  
 262 cytoskeleton. First, cellular and nuclear morphology was quantified from epifluorescence images of  
 263 cells labelled with phalloidin for F-actin and DAPI for the nucleus (Figure 2A). Human dermal

264 fibroblasts from older donors displayed a significant increase in cell area compared to cells from the  
 265 neonatal donor Cell surface area was around  $2000 \mu\text{m}^2$  (CoV = 58%) for cells for the neonatal donor,  
 266 while for cells from adult donors, the surface area was larger and ranging from  $3000\text{-}7000 \mu\text{m}^2$  (CoV  
 267 = 60%), reaching a larger than 2-fold increase when comparing cells from neonatal donor to cells  
 268 from oldest donor (Figure 2B). With increasing donor age, cells also underwent changes in their  
 269 aspect ratio, from a spindle shape to large solid spread (Figure 2C). Interestingly, the changes in  
 270 cellular morphology and specifically the increases in cell spread area had only a weak correlation  
 271 with changes in nuclear volume. In this regard, the nucleus volume increased significantly only  
 272 when comparing cells from the youngest to the oldest donors (Figure 2D).



273

274 **Figure 2.** Cells from aged donors exhibited changes in cellular and nuclear morphology. (A)  
 275 Representative epifluorescence images showing increased cell area and F-actin organization of cells  
 276 from donors at different age. F-actin labelled with Phalloidin (red), nucleus DAPI (blue). Scale bars  
 277 represent  $20 \mu\text{m}$ . (B) Corresponding plot showing the increased cell area of cells from aged donors  
 278 compared to neonatal donor. (C) There was a significant decrease in aspect ratio of cells from aged  
 279 donors (\*\* $p < 0.001$ , Mann Whitney U test). (D) Nucleus relative volume increased for cells from aged  
 280 donor (\*\* $p < 0.001$ , Mann Whitney U test). Data plotted from at least three independent experiments  
 281 as geometric mean with quartiles, total cell number varied between 282-620, with  $\sim 100$  cells per


282 repeat. (E) Representative epifluorescence images of YAP localisation in cells from neonatal and  
283 adult donors. Cells are labelled, nucleus DAPI (blue), YAP (green). Scale bars represent 20  $\mu\text{m}$ . (F)  
284 Immunostaining analysis showing a significant reduction of ratio of YAP nuclear to cytoplasmic in  
285 cells from aged donors. (G) Corresponding plot showing correlation between YAP localisation to cell  
286 area. Independantly to donor age, in all age groups larger cells have less nuclear YAP. Data is plotted  
287 from three independent experiments and presented as mean values with SD (nonparametric one way  
288 ANOVA test, \*\*\*  $p < 0.001$ ). Number of cells ranged between (68-202).

289 Previous studies have suggested that YAP localization is regulated by cell-matrix interactions  
290 and intracellular tension during cell attachment and spreading [38]. Since our results showed  
291 age-associated changes in cell biophysical properties and specifically in cell spreading area, we  
292 examined whether they would lead to changes in YAP intracellular localization. We cultured cells at  
293 low density and labelled them with phalloidin for F-actin, YAP primary antibody and DAPI for cell  
294 nucleus. In this experiment phalloidin staining was used to readily quantify cell area and we used  
295 imaging protocols as described above. To measure YAP localisation, specifically whether YAP is  
296 localised preferentially in cell nucleus or cytosol, we quantified YAP nuclear to cytosolic ratio as  
297 done by others [39,40]. Representative fluorescence images show that YAP is more concentrated in  
298 the cell nucleus in cells from the neonatal donor compared to cells from older donors (Figure 2E). In  
299 particular, cells from oldest donor show a 1.6-fold reduction in YAP ratio compared to cells from the  
300 neonatal donor (Figure 2F). We next verified whether there was any connection between YAP  
301 localisation and cell area and found that increasing cell areas lead to decreased YAP ratios in a  
302 strongly correlated manner. Surprisingly, the relationship between YAP localization and donor age  
303 appeared to be only secondary, as shown by the strong overlap between data points for all donor  
304 ages in figure 2G. These results suggest that changes in YAP ratio are primarily associated with  
305 changes in cell area, which is on its own regulated by donor age.

### 306 3.3. *Vimentin rather than F-actin or microtubules is dominantly increased in human dermal fibroblast ageing*

307 The three main cytoskeletons, F-actin, microtubules and the intermediate filament vimentin are  
308 all key players in maintaining cell morphological and biophysical properties. Since our results  
309 indicated that donor ageing modulated cell biophysical properties and morphology, we next  
310 investigated whether this was associated with changes in F-actin, tubulin and the intermediate  
311 filament vimentin. Similar to previous immunostaining experiments, cells were cultured at low  
312 density and then stained with phalloidin for F-actin and primary antibodies against tubulin or  
313 vimentin. Single cells were imaged using epifluorescence microscope equipped with 20x objective.  
314 Quantification algorithms were used to determine cell morphology as well as properties of fibre  
315 architecture and overall organisation. Representative images show that cells from aged donors had  
316 more pronounced actin fibres compared to cells from the neonatal donor (Figure 2A) as well as  
317 similar changes for tubulin and vimentin fibres (Figure 3A). In particular we found a significant  
318 increase in F-actin amount alongside a significant decrease in actin fibre length and thickness in cells  
319 from aged donors compared to cells from neonatal donor (Figure S5, A,B and C). Donor age had an  
320 effect not only on F-actin, but also on vimentin fibre morphology. The results indicate that cells from  
321 older donors have an increased amount of vimentin with longer and thicker fibres (Figure S5, D,E  
322 and F). Similarly, cells from older donors showed increased levels of tubulin amount with shorter  
323 and thicker fibres compared to cells from the neonatal donor (Figure S5, G,H and I). Together, these  
324 data show that donor aging is associated with changes in all three cytoskeletons. We then  
325 normalised our cytoskeletal amount data to account for differences in primary and secondary  
326 antibody affinities that lead to dissimilar amounts of fluorescence intensities being measured for  
327 each stained cytoskeletal protein. When reporting relative changes against the measured  
328 cytoskeletal amount of the neonatal donor, we found that vimentin displayed the largest increase  
329 with donor age (Figure 3, B,C and D).






330

331 **Figure 3.** Age has the highest influence on intermediate filaments. (A) Representative  
 332 epifluorescence images showing tubulin and vimentin organization of cells from donors at different  
 333 age. Fibres labelled against tubulin and vimentin (green). Scale bars represent 20  $\mu\text{m}$ . Corresponding  
 334 plot of three cytoskeletons showing relative changes in (B) fibre amount, (C) fibre length and (D)  
 335 fibre thickness. Vimentin is showing the highest changes compared to F-actin and tubulin. Data is  
 336 plotted from three independent experiments and normalised to neonatal donor to show the  
 337 magnitude of changes. The data of all cytoskeletons with real values are presented in supplementary  
 338 figure (S5).

339 Accordingly, we decided to further focus on the intermediate filament vimentin and explore its  
 340 dynamics. To study the dynamics of vimentin fibres in live cells, we developed a single cell  
 341 reattachment experiment as follows. Cells at low density were initially transfected with vimentin  
 342 plasmid and treated with trypsin for a short period of time until they displayed a rounded up  
 343 morphology without being completely detached. Immediately afterwards, trypsin was gently  
 344 exchanged with fresh medium and selected cells were imaged with a 20x objective. Images were  
 345 taken every 10 minutes for 10 hours. During the reattachment process, changes in cell area and  
 346 vimentin fibre dynamics were clearly observed (Movie S1 and S2). We then investigated whether  
 347 vimentin fibre remodelling rate during reattachment was affected by donor age. To do so, vimentin  
 348 fibre amount was quantified for all the frames in the videos obtained during the reattachment  
 349 process. The representative plots of vimentin fibre versus time show that the amount of vimentin  
 350 reaches a plateau, whose value increases in cells from older donors (Figure 4A), in a fashion similar

351 to the results obtained for immunostaining. To extract additional information about reorganization  
 352 dynamics, we fitted our data using a one-phase exponential decay function:  $y = y_0 + (plateau -$   
 353  $y_0) \cdot (1 - \exp(-k \cdot x))$ . From the fitted data, we derived parameters such as half life, computed as  
 354  $1/k$ ; or span, computed as  $(plateau - y_0)$ . The half-life parameter estimates the dynamics of  
 355 vimentin during reattachment, while span estimates the amount of vimentin once the cell has  
 356 established full reattachment (Figure 4B). Our results show that vimentin fibre remodelling rate is  
 357 faster for neonatal cells (smaller values for half life) and decreases with donor age (Figure 4C). The  
 358 span results again agree with immunofluorescence data, which show increased vimentin  
 359 steady-state amount in older cells (Figure 4D).



360

361 **Figure 4.** Vimentin fibre remodeling rate is faster in cells from young donor. (A) Representative plot  
 362 shows the temporal changes in vimentin fibre intensity during reattachment time of cells from  
 363 different donor ages. (B) An exponential model was used to fit the data and to determine parameters  
 364 such half life and span. (C) There was a statistically significant difference in vimentin fibre  
 365 remodeling half life, indicating slower vimentin remodelling rate for adult cells. (D) The span  
 366 indicates that the vimentin fibre amount is higher in adult cells. Data is plotted from at least three  
 367 independent experiments and presented as mean values with SD (\*\*\*)  $p < 0.001$ , obtained using  
 368 Dunnett test against neonatal donor). Cell number varies between (26-35).


369 **3.4. Drug-induced changes in vimentin assembly are correlated with changes in cell motility and Young's**  
 370 **modulus**

371 Given that cells from older donors displayed reduced motility and increased amount of  
 372 vimentin fibres, we next explored whether biophysical properties of cells could be modulated using  
 373 drugs believed to primarily affect vimentin assembly. To do so, we used withaferin A and

374 acrylamide and monitored single cell migration after treatments with said drugs in neonatal and  
 375 adult cells (using 47 year-old donor source). Cells at low density were transfected with  
 376 vimentin-GFP for 72 hours prior drug treatment and time lapse fluorescence images were taken only  
 377 on transfected and well attached cells. Considering the large variability of single cell motility, we  
 378 decided to image the same individual cells before and after drug treatment. Therefore, cells were  
 379 imaged for 1 hour before treatment and 3 hours after drug treatment. Cell velocity was measured as  
 380 previously described. In parallel, a different set of cells treated with the same drugs were  
 381 immunostained with phalloidin for F-actin and primary antibody against vimentin to quantify their  
 382 assembly.

383 First, we investigated the potential effect of withaferin A treatment on cell migration and  
 384 vimentin assembly. Withaferin A treatment caused a reduction in cell motility and increased the  
 385 amount of vimentin assembled in fibres for cells from the neonatal donor (Figure S6, A,B and C).  
 386 Similar results in terms of cell motility and vimentin assembly were observed in cells from the older  
 387 donor (Figure S6, D,E and F). Of note withaferin A treatment caused aggregation of vimentin fibres,  
 388 which was already observed in previous study [41] as well.

389 Next we investigated the effect of acrylamide treatment using the same approach as before.  
 390 Surprisingly, acrylamide treatment had no effect on cell migration of cells from neonatal donor and  
 391 showed a minor effect on vimentin and F-actin fibres assembly (Figure S7, A,B and C). However, a  
 392 significant increase in cell motility alongside a significant reduction in vimentin fibres was found for  
 393 cells from the aged donor (Figure S7, D,E and F). These results suggest that withaferin A and  
 394 acrylamide have an opposite effect on vimentin assembly in our cells, which is partially dependant  
 395 on donor age. Therefore, we pooled all results together from withaferin A and acrylamide  
 396 treatments using only the two highest dosages. Surprisingly, we found a strong correlation between  
 397 relative changes in cell velocity and relative changes in vimentin amount due to drug treatments. In  
 398 particular, withaferin A caused a reduction of cell velocity and increased vimentin amount;  
 399 meanwhile acrylamide treatment increased cell velocity and reduced vimentin amount (Figure 5A).  
 400 To confirm that this effect was primarily associated with changes in vimentin fibres, we verified that  
 401 there was no correlation between cell velocity and F-actin relative changes with either withaferin A  
 402 or acrylamide treatments (Figure 5B).




403

404 **Figure 5.** Acrylamide and withaferin A treatments have a reversible effect on dermal fibroblast  
 405 migration and vimentin and actin fibres. (A) Corresponding plot showing the increased cell velocity  
 406 of cells treated with acrylamide and decreased cell velocity of cells treated with withaferin A, which  
 407 correlated with changes in vimentin amount. (B) The plot shows that cell velocity was not correlated  
 408 to changes of F-actin amount. Plots are presented using acrylamide 4 and 6 mM, and withaferin A 2.5  
 409 and 5  $\mu$ M concentrations. The data of all concentrations is presented in supplementary figures  
 410 (S6-S7).

411 Since withaferin A and acrylamide had a modulatory effect on vimentin fibres, which was  
 412 observed alongside changes in cell motility, we next investigated whether a similar correlation was

413 observed for Young's modulus ( $E$ ) and whether those effects depended on the mechanical structure  
 414 being probed. Atomic force microscope was employed to measure the viscoelastic properties of cells  
 415 treated with withaferin A or acrylamide. Force indentation curves were taken by probing cells  
 416 treated with withaferin A or acrylamide after 3 hours. We found that withaferin A treatment  
 417 increased  $E_{CSK}$  and  $E_{cort}$  of cells from the neonatal donor (Figure S8, A and B), even though significant  
 418 differences were only observed for  $E_{cort}$  at the highest concentration. Conversely, withaferin A  
 419 treatment had no effect on cells from the adult donor (Figure S8, E and F), suggesting that it was  
 420 unable to further stiffen the already reinforced cytoskeleton of old cells. Similarly, we investigated  
 421 the effect of acrylamide treatment on  $E$  and found that cells from both neonatal and adult donors  
 422 showed a significant reduction in  $E_{CSK}$  (Figure S8, C and G), while  $E_{cort}$  was not affected for both  
 423 donor ages (Figure S8, D and H). This result is not surprising given that the vimentin network is  
 424 primarily localized deep in the cell body, whereas actin is the mechanically-dominant structure in  
 425 the cell cortex.

426 Together, these results suggest that there is a significant correlation between  $E_{CSK}$  and vimentin  
 427 assembly (Figure 6, A and B), which parallels the correlation between cell migration speed and  
 428 vimentin assembly. While we find that withaferin A and acrylamide treatments had a mild effect on  
 429 actin assembly, this was not correlated with  $E_{CSK}$ ,  $E_{cort}$  (Figure 6, C and D) or cell migration speed.



430

431 **Figure 6. Changes in vimentin but not actin amount modulate  $E_{CSK}$  and  $E_{cort}$ .** Corresponding plots  
 432 of (A) cytoskeleton and (B) cortical stiffness show a significant correlation to vimentin amount. Cell  
 433 treatments with withaferin A and acrylamide correlate with increased  $E$  of cells with higher amount  
 434 of vimentin. Changes actin amount in treated cells with not effect cell (C) cytoskeletal and (D) cortical  
 435 Young's modulus. Plots are presented using acrylamide 4 and 6 mM, and withaferin A 2.5 and 5  $\mu$ M  
 436 concentrations. The data of drug treatment and significant differences presented in supplementary  
 437 figures (S8).

438 Accordingly, our findings indicate that for human dermal fibroblasts, cell biophysical  
 439 properties such cell motility and Young's modulus are primarily correlated with amounts of  
 440 vimentin assembled in filaments. Specifically, treatments on older cells that lower the amount of

441 vimentin to levels comparable to those displayed by younger cells also result in the rejuvenation of  
442 the biophysical and migratory phenotype displayed by older cells.

#### 443 4. Discussion

444 In this study, human dermal fibroblast cells from donors of different ages were used as a model  
445 to study how single cell migration, biophysical and morphological properties are altered by donor  
446 age. In recent years, a number of studies have focused on characterizing delays in wound healing  
447 associated with cellular aging [42,43]. In particular, cell velocity is considered a key biophysical  
448 parameter, which is widely used to characterize the cell's ability to move from a healthy to a  
449 diseased location within its host tissue [44–47]. Previous studies have focused on proteasome  
450 content and activity to understand cell senescence [48], but little is known on how cell biophysical  
451 and morphological properties are associated with donor age. Here, we show that donor aging  
452 resulted in reduction of cell motility, which was associated with cell stiffening and increased  
453 amounts of F-actin, tubulin and dominantly vimentin.

454 The cytoskeleton is a complex system with a broad range of functions such as the formation and  
455 maintenance of cell morphology, polarity, cell division and migration. Cells from aged donors  
456 displayed changes in cell morphology with a reduction in cell motility and increased mechanical  
457 strength. It is thus expected that the integrity of the cytoskeleton is altered, not only at the  
458 macrostructure but also at the nanostructure level. F-actin fibres are believed to be key factors in  
459 regulating cell shape and motility, although microtubules and intermediate filaments play a crucial  
460 role too. In this connection, changes of F-actin structure and amount have been reported in cells  
461 undergoing induced senescence. For one study, cells had thicker fibres but the total amount of  
462 F-actin remained the same [36]. Meanwhile in another study, the total amount of actin protein was  
463 observed to be reduced in cells from aged donors [49]. Among other cytoskeletal networks, changes  
464 of the intermediate filament vimentin have been reported in several types of senescent cells. Using  
465 extensive passage as a surrogate for cellular aging, vimentin was found to develop thick and long  
466 fibres, while cells at early passage had thin and short fibres [50]. Similarly, it has been reported that  
467 the amount of tubulin fibres also increases in senescent cells [37]. In this study, we report for the first  
468 time that all three cytoskeletons are altered by donor age. F-actin, tubulin and vimentin all increased  
469 in abundance for cells from adult donors, displaying shorter and thinner fibres for F-actin and  
470 tubulin, and longer and thicker fibres for vimentin. Focusing on vimentin as the most reinforced  
471 structure, we found that vimentin fibre remodelling rate is slower, with higher level of protein in  
472 cells from adult donors. These changes suggest that the increased assembly of vimentin filaments  
473 observed in cells from older donors plays an important role in the aberrant biophysical properties  
474 associated with donor aging.

475 Yes-associated protein (YAP) has been shown to be regulated by cell senescence [51]. Here, we  
476 show that changes in YAP ratio are most likely primarily associated with changes in cellular gross  
477 morphology (Figure 2G). Therefore, YAP ratio changes are indirectly dependent on donor age, as  
478 cells from aged donors display larger spreading areas that leads to lower YAP ratios. On a different  
479 note, observations by others indicate that senescent cells have larger spread areas [52]. While on  
480 average, the population of cells from the A62 donor displayed a light increase in senescence  
481 (reduced proliferation) marker p21, we didn't find correlation trends between nuclear expression of  
482 p21 and cell spread area when we performed our analysis on a single-cell basis. Put together, these  
483 suggest that the aberrations in biophysical parameters we observe for cells from older donors are  
484 likely linked to changes in vimentin assembly, rather than being linked to the onset of senescence. **Of  
485 note, one a different unpublished study, we find that extensive passaging (more than 15 passages) of  
486 neonatal cells leads to similar biophysical properties to those displayed by early-passage cells from  
487 older donors (data not shown). Conversely, extensive passaging of cells from older donors doesn't  
488 result in further reinforcement of the cytoskeleton and cell mechanics, but rather leads to an aberrant  
489 mechanical phenotype that may represent the onset of senescence (data not shown).**

490 Vimentin has been known to play a key role in cell migration. In migrating fibroblasts, the  
491 nucleus is surrounded by an abundance of vimentin filaments, which extend into the tail of the cell.

492 On the contrary, vimentin monomers and short filaments are localized at the leading edge. These  
493 intracellular regional changes in vimentin structure and organization are responsible for regulating  
494 protrusion activity. In addition, serum starvation in fibroblasts caused reduced motility and the local  
495 break down of the vimentin network [53]. Similarly, vimentin assembly is essential for wound  
496 healing in several animal models and cells in culture [25,26,54]. Fibroblasts from vimentin-deficient  
497 mouse exhibited a reduction in cell motility, defects in directionality and on their ability to organize  
498 collagen [25,55], while vimentin overexpression caused increased cell motility of breast cancer cells  
499 [56]. These findings indicate that vimentin filaments play an important role not only in cell  
500 mechanical support but also in cell motility and that an exquisite fine tuning of its amount and  
501 organization is required for optimal cell migration.

502 The contribution of vimentin organization to cell motility and mechanical properties can be also  
503 assessed using drugs against vimentin. Of note, the use of drugs targeting the polymerization of  
504 vimentin monomers into filaments rather than the use of siRNA against vimentin protein expression  
505 is an approach that parallels the use of Cytochalasin D or Latrunculin A against the assembly of  
506 G-actin monomers into F-actin fibres to understand the structural role of stress fibres on cell  
507 mechanics. That being said, the existing biochemical toolkit to target vimentin is still very limited  
508 and not fully characterized. Accordingly, the two gold-standard drugs used in the literature,  
509 Withaferin A and Acrylamide, may also affect other cytoskeletal structures or signaling pathways in  
510 addition to modulating vimentin filament assembly. In our experiments, Withaferin A treatment  
511 induced disruption of vimentin organization and lead to the formation of aggregates, which are  
512 believed to be associated with changes in cell shape, reduction in cell motility [57] and cell softening  
513 [41]. Similarly, cells treated with acrylamide have been reported to display reduced stiffness, as  
514 evaluated by applying large strains on cells embedded in alginate gels [58]. Interestingly, in our  
515 study, we find that cells from both neonatal and adult donors treated with withaferin A at  
516 concentrations of 1  $\mu$ M – 5  $\mu$ M displayed reduced cell motility and increased cell stiffness which was  
517 likely associated with aggregation of vimentin. We thus hypothesize that the observed cell stiffening  
518 is associated with changes in vimentin organization from long filaments to short structures and  
519 aggregates. The aggregates then formed solid, stiff structures, which increased cell stiffness.  
520 Furthermore, we find that withaferin A-associated changes in vimentin organization, cell motility  
521 and Young's modulus are dose and donor-age dependent. In contrast, cells treated with acrylamide  
522 exhibited increased cell motility and reduced Young's modulus, which was correlated with a  
523 reduction of vimentin assembly. We and others have shown that the modulation in the assembly of  
524 stress fibres, microtubules and intermediate filaments is often analogous and closely tied to cell  
525 spread area [30,35]. It is thus plausible that the drug treatments against vimentin used here did also  
526 induce changes in the assembly of other cytoskeletal filaments. Nevertheless, in our experiments we  
527 used shorter treatments and lower concentrations than those used by others when reporting  
528 detrimental effects of these drugs on all cytoskeletons [59–61]. Similarly, the strong correlation  
529 observed between vimentin assembly and biophysical properties was largely lost when we  
530 performed similar analysis using instead levels of actin filamentous assembly. Together, our results  
531 suggest that in the cellular model used here, vimentin assembly has a dominant role in modulating  
532 the biophysical and migratory behaviours. It is worth mentioning that experiments by others on  
533 vimentin knock-out cells show aberrant biophysical behaviors, with a significant decrease in cellular  
534 stiffness as well as migration speeds [62,63]. Accordingly, we hypothesize that the amount of  
535 vimentin fibrillar assembly, rather than overall level of vimentin protein expression, plays a crucial  
536 role in fine-tuning cell mechanics to attain optimal migration rates. It thus follows that a complete  
537 inhibition of vimentin assembly does not necessary increase cell migration further, and that a certain  
538 amount of vimentin is likely necessary for optimal cell motility.

539 In summary, and to highlight the relevance of our results, we show that vimentin dominates the  
540 changes in cytoskeleton organization and assembly in human dermal fibroblast cells and may thus  
541 play a key role in the aberrant behaviour and impaired function displayed by this cell type in the  
542 course of human ageing. Accordingly, we propose that vimentin might serve as a suitable  
543 therapeutic target especially for aging-related diseases. We further propose that biophysical

544 properties such cell motility and mechanical properties are strongly correlated to vimentin amount  
545 and can thus be readily used as high-throughput biomarkers on drug screening assays in the search  
546 for new anti-aging therapies.  
547

548 Supplementary Materials: The following are available online at [www.mdpi.com/xxx/s1](http://www.mdpi.com/xxx/s1), Figure S1: AFM  
549 topography images of cells from different donors, Figure S2: Donor ageing reduces cell migration of cell  
550 monolayer, Figure S3: Correlation between *p21* cell senescence marker and donor ageing, Figure S4: Expression  
551 of alpha- smooth muscle actin in cells from different donors, Figure S5: Cells from aged donors exhibited  
552 changes in the main three cytoskeletons, Figure S6: Withaferin A treatment reduced cell migration  
553 independantly to donor age, Figure S7: Acrylamide treatment has a higher effect on cell migration for cells from  
554 aged donor, Figure S8: The effect of withaferin A and acrylamide treatments on E, Figure S9: Changes of cell  
555 area during chemical and biological reattachment, Video S1: Reattachment process of cell from neonatal donor,  
556 Video S2: Reattachment process of cell from adult donor, Video S3: Cell division of NIH 3T3 during  
557 reattachment process, Supplementary methods: Validation of cell reattachment.

558 **Author Contributions:** K.S and N.G designed the study, K.S conducted experiments. Both authors contributed  
559 to analysing, interpreting the data and drafting the manuscript.

560 **Funding:** This work was supported by a Dunhill Medical Trust grant (R454/1115) and a BBSRC grant  
561 (BB/P006108/1).

562 **Acknowledgments:** The authors wish to thank Prof. David Lee for helpful discussion of this work.

563 **Conflicts of Interest:** The authors declare no competing financial interest.

## 564 References

- 565 1. Phillip, J.M.; Aifuwa, I.; Walston, J.; Wirtz, D. The Mechanobiology of Aging. *Annu. Rev.*  
566 *Biomed. Eng.* **2015**, *17*, 113–141.
- 567 2. Baker, D.J.; Childs, B.G.; Durik, M.; Wijers, M.E.; Sieben, C.J.; Zhong, J.; A. Saltness, R.;  
568 Jeganathan, K.B.; Verzosa, G.C.; Pezeshki, A.; et al. Naturally occurring p16Ink4a-positive  
569 cells shorten healthy lifespan. *Nature* **2016**, *530*, 184.
- 570 3. Jeon, O.H.; Kim, C.; Laberge, R.-M.; Demaria, M.; Rathod, S.; Vasserot, A.P.; Chung, J.W.;  
571 Kim, D.H.; Poon, Y.; David, N.; et al. Local clearance of senescent cells attenuates the  
572 development of post-traumatic osteoarthritis and creates a pro-regenerative environment.  
573 *Nat. Med.* **2017**, *23*, 775.
- 574 4. Chilosi, M.; Carloni, A.; Rossi, A.; Poletti, V. Premature lung aging and cellular senescence in  
575 the pathogenesis of idiopathic pulmonary fibrosis and COPD/emphysema. *Transl. Res.* **2013**,  
576 *162*, 156–173.
- 577 5. Liton, P.B.; Challa, P.; Stinnett, S.; Luna, C.; Epstein, D.L.; Gonzalez, P. Cellular senescence in  
578 the glaucomatous outflow pathway. *Exp. Gerontol.* **2005**, *40*, 745–748.
- 579 6. Thangavel, C.; Dean, J.L.; Ertel, A.; Knudsen, K.E.; Aldaz, C.M.; Witkiewicz, A.K.; Clarke, R.;  
580 Knudsen, E.S. Therapeutically activating RB: reestablishing cell cycle control in endocrine  
581 therapy-resistant breast cancer. *Endocr. Relat. Cancer* **2011**, *18*, 333–345.
- 582 7. Liao, H.; He, H.; Chen, Y.; Zeng, F.; Huang, J.; Wu, L.; Chen, Y. Effects of long-term serial cell  
583 passaging on cell spreading, migration, and cell-surface ultrastructures of cultured vascular  
584 endothelial cells. *Cytotechnology* **2014**, *66*, 229–238.

- 585 8. Shi, Q.; Aida, K.; Vandeberg, J.L.; Wang, X.L. Passage-dependent changes in baboon  
586 endothelial cells—relevance to in vitro aging. *DNA Cell Biol.* **2004**, *23*, 502–509.
- 587 9. Chiou, Y.; Lin, H.; Tang, M.; Lin, H.; Yeh, M. The Influence of Physical and Physiological  
588 Cues on Atomic Force Microscopy-Based Cell Stiffness Assessment. **2013**, *8*.
- 589 10. Morgan, J.T.; Raghunathan, V.K.; Chang, Y.-R.; Murphy, C.J.; Russell, P. The intrinsic  
590 stiffness of human trabecular meshwork cells increases with senescence. *Oncotarget* **2015**, *6*.
- 591 11. Yang, L.; Suwa, T.; Wright, W.E.; Shay, J.W.; Hornsby, P.J. Telomere shortening and decline  
592 in replicative potential as a function of donor age in human adrenocortical cells. *Mech. Ageing*  
593 *Dev.* **2001**, *122*, 1685–1694.
- 594 12. Phillip, J.M.; Wu, P.H.; Gilkes, D.M.; Williams, W.; McGovern, S.; Daya, J.; Chen, J.; Aifuwa,  
595 I.; Lee, J.S.H.; Fan, R.; et al. Biophysical and biomolecular determination of cellular age in  
596 humans. *Nat. Biomed. Eng.* **2017**, *1*.
- 597 13. Schulze, C.; Wetzel, F.; Kueper, T.; Malsen, A.; Muhr, G.; Jaspers, S.; Blatt, T.; Wittern, K.P.;  
598 Wenck, H.; Käs, J.A. Stiffening of human skin fibroblasts with age. *Clin. Plast. Surg.* **2012**, *39*,  
599 9–20.
- 600 14. Berdyeva, T.K.; Woodworth, C.D.; Sokolov, I. Human epithelial cells increase their rigidity  
601 with ageing in vitro: Direct measurements. *Phys. Med. Biol.* **2005**, *50*, 81–92.
- 602 15. Dulińska-Molak, I.; Pasikowska, M.; Pogoda, K.; Lewandowska, M.; Eris, I.; Lekka, M.  
603 Age-related changes in the mechanical properties of human fibroblasts and its prospective  
604 reversal after anti-wrinkle tripeptide treatment. *Int. J. Pept. Res. Ther.* **2014**, *20*, 77–85.
- 605 16. Fenteany, G.; Zhu, S. Small-molecule inhibitors of actin dynamics and cell motility. *Curr. Top.*  
606 *Med. Chem.* **2003**, *3*, 593–616.
- 607 17. Burnette, D.T.; Manley, S.; Sengupta, P.; Sougrat, R.; Davidson, M.W.; Kachar, B.;  
608 Lippincott-schwartz, J. A role for actin arcs in the leading-edge advance of migrating cells.  
609 *Nat. Cell Biol.* **2011**, *13*, 371–381.
- 610 18. Stricker, J.; Falzone, T.; Gardel, M.L. Mechanics of the F-actin cytoskeleton. *J. Biomech.* **2010**,  
611 *43*, 9–14.
- 612 19. Icard-arcizet, D.; Cardoso, O.; Richert, A.; He, S. Cell Stiffening in Response to External Stress  
613 is Correlated to Actin Recruitment. **2008**, *94*, 2906–2913.
- 614 20. Petrie, R.J.; Koo, H.; Yamada, K.M. Generation of compartmentalized pressure by a nuclear  
615 piston governs cell motility in a 3D matrix. *Science (80-. )*. **2014**, *345*, 1062 LP – 1065.
- 616 21. Costigliola, N.; Ding, L.; Burckhardt, C.J.; Han, S.J.; Gutierrez, E.; Mota, A.; Groisman, A.;  
617 Mitchison, T.J.; Danuser, G. Vimentin fibers orient traction stress. *Proc. Natl. Acad. Sci.* **2017**,  
618 *114*, 5195–5200.



- 619 22. Cheng, F.; Shen, Y.; Mohanasundaram, P.; Lindström, M.; Ivaska, J.; Ny, T.; Eriksson, J.E.  
620 Vimentin coordinates fibroblast proliferation and keratinocyte differentiation in wound  
621 healing via TGF- $\beta$ -Slug signaling. *Proc. Natl. Acad. Sci.* **2016**, *113*, E4320–E4327.
- 622 23. De Pascalis, C.; Pérez-González, C.; Seetharaman, S.; Boëda, B.; Vianay, B.; Burute, M.; Leduc,  
623 C.; Borghi, N.; Trepat, X.; Etienne-Manneville, S. Intermediate filaments control collective  
624 migration by restricting traction forces and sustaining cell-cell contacts. *J. Cell Biol.* **2018**, *217*,  
625 3031–3044.
- 626 24. Guo, M.; Ehrlicher, A.J.; Mahammad, S.; Fabich, H.; Jensen, M.H.; Moore, J.R.; Fredberg, J.J.;  
627 Goldman, R.D.; Weitz, D.A. The role of vimentin intermediate filaments in cortical and  
628 cytoplasmic mechanics. *Biophys. J.* **2013**, *105*, 1562–1568.
- 629 25. Eckes, B.; Colucci-Guyon, E.; Smola, H.; Nodder, S.; Babinet, C.; Krieg, T.; Martin, P. Impaired  
630 wound healing in embryonic and adult mice lacking vimentin. *J. Cell Sci.* **2000**, *113*, 2455–  
631 2462.
- 632 26. Rogel, M.R.; Soni, P.N.; Troken, J.R.; Sitikov, A.; Trejo, H.E.; Ridge, K.M. Vimentin is  
633 sufficient and required for wound repair and remodeling in alveolar epithelial cells. *FASEB J.*  
634 **2011**, *25*, 3873–3883.
- 635 27. Wei, J.; Xu, G.; Wu, M.; Zhang, Y.; Li, Q.; Liu, P.; Zhu, T.; Song, A.; Zhao, L.; Han, Z.; et al.  
636 Overexpression of vimentin contributes to prostate cancer invasion and metastasis via Src  
637 regulation. *Anticancer Res.* **2008**, *28*, 327–334.
- 638 28. Tanaka, H.; Goto, H.; Inoko, A.; Makihara, H.; Enomoto, A.; Horimoto, K.; Matsuyama, M.;  
639 Kurita, K.; Izawa, I.; Inagaki, M. Cytokinetic Failure-induced Tetraploidy Develops into  
640 Aneuploidy, Triggering Skin Aging in Phosphovimentin-deficient Mice. *J. Biol. Chem.* **2015**,  
641 *290*, 12984–12998.
- 642 29. Kueper, T.; Grune, T.; Prahl, S.; Lenz, H.; Welge, V.; Biernoth, T.; Vogt, Y.; Muhr, G.-M.;  
643 Gaemlich, A.; Jung, T.; et al. Vimentin Is the Specific Target in Skin Glycation: STRUCTURAL  
644 PREREQUISITES, FUNCTIONAL CONSEQUENCES, AND ROLE IN SKIN AGING . *J. Biol.*  
645 *Chem.* **2007**, *282*, 23427–23436.
- 646 30. Flores, L.R.; Keeling, M.C.; Zhang, X.; Sliogeryte, K.; Gavara, N. Lifeact-GFP alters F-actin  
647 organization, cellular morphology and biophysical behaviour. *Sci. Rep.* **2019**, *9*, 1–13.
- 648 31. Gavara, N. Combined strategies for optimal detection of the contact point in AFM  
649 force-indentation curves obtained on thin samples and adherent cells. *Sci. Rep.* **2016**, *6*, 1–13.
- 650 32. Gavara, N.; Chadwick, R.S. Determination of the elastic moduli of thin samples and adherent  
651 cells using conical atomic force microscope tips. *Nat. Nanotechnol.* **2012**, *7*, 733–736.
- 652 33. Pogoda, K.; Jaczewska, J.; Wiltowska-Zuber, J.; Klymenko, O.; Zuber, K.; Fornal, M.; Lekka,  
653 M. Depth-sensing analysis of cytoskeleton organization based on AFM data. *Eur. Biophys. J.*

- 654           **2012**, *41*, 79–87.
- 655   34.   Rebello, L.M.; De Sousa, J.S.; Mendes Filho, J.; Radmacher, M. Comparison of the viscoelastic  
656       properties of cells from different kidney cancer phenotypes measured with atomic force  
657       microscopy. *Nanotechnology* **2013**, *24*.
- 658   35.   Keeling, M.C.; Flores, L.R.; Dodhy, A.H.; Murray, E.R.; Gavara, N. Actomyosin and vimentin  
659       cytoskeletal networks regulate nuclear shape, mechanics and chromatin organization. *Sci.*  
660       *Rep.* **2017**, *7*, 1–14.
- 661   36.   Chen, Q.M.; Tu, V.C.; Catania, J.; Burton, M.; Toussaint, O.; Dilley, T. Involvement of Rb  
662       family proteins, focal adhesion proteins and protein synthesis in senescent morphogenesis  
663       induced by hydrogen peroxide. *J. Cell Sci.* **2000**, *113* ( Pt 2, 4087–97).
- 664   37.   Wang, E.; Gundersen, D. Increased organization of cytoskeleton accompanying the aging of  
665       human fibroblasts in vitro. *Exp. Cell Res.* **1984**, *154*, 191–202.
- 666   38.   Dupont, S. Role of YAP/TAZ in cell-matrix adhesion-mediated signalling and  
667       mechanotransduction. *Exp. Cell Res.* **2016**, *343*, 42–53.
- 668   39.   Nardone, G.; Oliver-De La Cruz, J.; Vrbsky, J.; Martini, C.; Pribyl, J.; Skládál, P.; Pešl, M.;  
669       Caluori, G.; Pagliari, S.; Martino, F.; et al. YAP regulates cell mechanics by controlling focal  
670       adhesion assembly. *Nat. Commun.* **2017**, *8*.
- 671   40.   Elosegui-Artola, A.; Andreu, I.; Beedle, A.E.M.; Lezamiz, A.; Uroz, M.; Kosmalska, A.J.; Oria,  
672       R.; Kechagia, J.Z.; Rico-Lastres, P.; Le Roux, A.L.; et al. Force Triggers YAP Nuclear Entry by  
673       Regulating Transport across Nuclear Pores. *Cell* **2017**, *171*, 1397-1410.e14.
- 674   41.   Gladilin, E.; Gonzalez, P.; Eils, R. Dissecting the contribution of actin and vimentin  
675       intermediate filaments to mechanical phenotype of suspended cells using high-throughput  
676       deformability measurements and computational modeling. *J. Biomech.* **2014**, *47*, 2598–2605.
- 677   42.   Acosta, J.C.; O’Loughlen, A.; Banito, A.; Guijarro, M. V.; Augert, A.; Raguz, S.; Fumagalli, M.;  
678       Da Costa, M.; Brown, C.; Popov, N.; et al. Chemokine Signaling via the CXCR2 Receptor  
679       Reinforces Senescence. *Cell* **2008**, *133*, 1006–1018.
- 680   43.   Noureddine, H.; Gary-Bobo, G.; Alifano, M.; Marcos, E.; Saker, M.; Vienney, N.; Amsellem,  
681       V.; Maitre, B.; Chaouat, A.; Chouaid, C.; et al. Pulmonary artery smooth muscle cell  
682       senescence is a pathogenic mechanism for pulmonary hypertension in chronic lung disease.  
683       *Circ. Res.* **2011**, *109*, 543–553.
- 684   44.   Chen, Q.-Y.; Xu, W.; Jiao, D.-M.; Wu, L.-J.; Song, J.; Yan, J.; Shi, J.-G. Silence of ezrin modifies  
685       migration and actin cytoskeleton rearrangements and enhances chemosensitivity of lung  
686       cancer cells in vitro. *Mol. Cell. Biochem.* **2013**, *377*, 207–18.
- 687   45.   Gerlitz, G.; Bustin, M. Efficient cell migration requires global chromatin condensation. *J. Cell*  
688       *Sci.* **2010**, *123*, 2207–17.

- 689 46. Rhee, S. Fibroblasts in three dimensional matrices: Cell migration and matrix remodeling.  
690 *Exp. Mol. Med.* **2009**, *41*, 858–865.
- 691 47. Friedl, P.; Wolf, K. Tumour-cell invasion and migration: diversity and escape mechanisms.  
692 *Nat. Rev. Cancer* **2003**, *3*, 362–74.
- 693 48. Hwang, J.S.; Hwang, J.S.; Chang, I.; Kim, S. Age-Associated Decrease in Proteasome Content  
694 and Activities in Human Dermal Fibroblasts: Restoration of Normal Level of Proteasome  
695 Subunits Reduces Aging Markers in Fibroblasts From Elderly Persons. *Journals Gerontol. Ser.*  
696 *A Biol. Sci. Med. Sci.* **2011**, *62*, 490–499.
- 697 49. Koji Nishio, A.I. Senescence-associated alterations of cytoskeleton: extraordinary production  
698 of vimentin that anchors cytoplasmic p53 in senescent human fibroblasts. *Histochem. Cell Biol.*  
699 **2005**, *123*, 263–273.
- 700 50. Nishio, K.; Inoue, A.; Qiao, S.; Kondo, H.; Mimura, A. Senescence and cytoskeleton:  
701 overproduction of vimentin induces senescent-like morphology in human fibroblasts.  
702 *Histochem. Cell Biol.* **2001**, *116*, 321–327.
- 703 51. Xie, Q.; Chen, J.; Feng, H.; Peng, S.; Adams, U.; Bai, Y.; Huang, L.; Li, J.; Huang, J.; Meng, S.; et  
704 al. YAP/TEAD-mediated transcription controls cellular senescence. *Cancer Res.* **2013**, *73*,  
705 3615–3624.
- 706 52. Kumazaki, T.; Robetorye, R.S.; Robetorye, S.C.; Smith, J.R. Fibronectin expression increases  
707 during in vitro cellular senescence: Correlation with increased cell area. *Exp. Cell Res.* **1991**,  
708 *195*, 13–19.
- 709 53. Helfand, B.T.; Mendez, M.G.; Prasanna Murthy, S.N.; Shumaker, D.K.; Grin, B.; Mahammad,  
710 S.; Aebi, U.; Wedig, T.; Wu, Y.I.; Hahn, K.M.; et al. Vimentin organization modulates the  
711 formation of lamellipodia. *Mol. Biol. Cell* **2011**, *22*.
- 712 54. Menko, A.S.; Bleaken, B.; Libowitz, A.; Zhang, L.; Stepp, M.A.; Walker, J. A central role for  
713 vimentin in regulating repair function during healing of the lens epithelium. *Mol. Biol. Cell*  
714 **2014**, *25*, 776–790.
- 715 55. Eckes, B.; Dogic, D.; Colucci-Guyon, E.; Wang, N.; Maniotis, A.; Ingber, D.; Merckling, A.;  
716 Langa, F.; Aumailley, M.; Delouvé, A.; et al. Impaired mechanical stability, migration and  
717 contractile capacity in vimentin-deficient fibroblasts. *J. Cell Sci.* **1998**, *111* ( Pt 1, 1897–907.
- 718 56. Hendrix, M.J.; Seftor, E.A.; Chu, Y.-W.; Trevor, K.T.; Seftor, R.E. Role of intermediate  
719 filaments in migration, invasion and metastasis. *Cancer Metastasis Rev.* **1996**, *15*, 507–525.
- 720 57. Ridge, K.M.; Shumaker, D.; Robert, A.; Hookway, C.; Gelfand, V.I.; Janmey, P.A.; Lowery, J.;  
721 Guo, M.; Weitz, D.A.; Kuczmariski, E. Methods for Determining the Cellular Functions of  
722 Vimentin Intermediate Filaments. **2016**, *568*, 389–426.
- 723 58. Haudenschild, D.R.; Chen, J.; Pang, N.; Steklov, N.; Grogan, S.P.; Lotz, M.K.; D’Lima, D.D.

- 724 Vimentin contributes to changes in chondrocyte stiffness in osteoarthritis. *J. Orthop. Res.* **2011**,  
725 29, 20–25.
- 726 59. Arocena, M. Effect of acrylamide on the cytoskeleton and apoptosis of bovine lens epithelial  
727 cells. *Cell Biol. Int.* **2006**, *30*, 1007–1012.
- 728 60. Grin, B.; Mahammad, S.; Wedig, T.; Cleland, M.M.; Tsai, L.; Herrmann, H.; Goldman, R.D.  
729 Withaferin a alters intermediate filament organization, cell shape and behavior. *PLoS One*  
730 **2012**, *7*, e39065.
- 731 61. Aggeler, J.; Seely, K. Cytoskeletal dynamics in rabbit synovial fibroblasts: I. Effects of  
732 acrylamide on intermediate filaments and microfilaments. *Cell Motil. Cytoskeleton* **1990**, *16*,  
733 110–120.
- 734 62. Lowery, J.; Kuczmarski, E.R.; Herrmann, H.; Goldman, R.D. Intermediate filaments play a  
735 pivotal role in regulating cell architecture and function. *J. Biol. Chem.* **2015**, *290*, 17145–17153.
- 736 63. Guo, M.; Ehrlicher, A.J.; Mahammad, S.; Fabich, H.; Jensen, M.H.; Moore, J.R.; Fredberg, J.J.;  
737 Goldman, R.D.; Weitz, D.A. The role of vimentin intermediate filaments in cortical and  
738 cytoplasmic mechanics. *Biophys. J.* **2013**, *105*, 1562–1568.

739

740



© 2019 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).

741